Opioid Overdose Reversal Medications
Opioid overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. The FDA continues to take actionable steps that support the availability and accessibility of opioid overdose reversal medications, such as naloxone and nalmefene, as well as the development of novel overdose reversal products. These life-saving medications are an important tool to reverse opioid overdose and can be administered by individuals without medical training, as shown on CDC’s website. They have no abuse potential, and some are available without a prescription.
Broadening Access to Opioid Overdose Reversal Medications
The FDA understands the importance of having opioid overdose reversal medications available and accessible for community use. To support these efforts, the FDA has approved naloxone nasal spray for purchase without prescription (over the counter, [OTC]), extended the shelf life of multiple naloxone products, approved multiple generic naloxone products, and hosted public workshops and stakeholder calls. Key activities include:
- FDA announces shelf-life extension for naloxone nasal spray
- FDA approves first generic OTC naloxone nasal spray
- FDA approves first OTC naloxone nasal spray
- FDA publishes guidance to increase public availability of and accessibility to naloxone
Advancing Evidence-Based Treatment for Opioid Overdose
The FDA approved two medications as safe and effective treatments for known or suspected opioid overdose: naloxone and nalmefene. FDA-approved medications can be found at Drugs@FDA. The FDA is working to identify additional treatment needs and support the development of new, evidence-based treatment options for opioid overdose. Key activities include:
- FDA approves first nalmefene hydrochloride auto-injector
- FDA approves the opioid analgesic risk evaluation and mitigation strategy modification, which includes updated information regarding opioid overdose reversal medications
- FDA, in collaboration with the Reagan-Udall Foundation for the FDA, hosts a public workshop on fatal overdoses
FDA Resources
- Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
- Medications for Opioid Use Disorder (MOUD)
- FDA Overdose Prevention Framework